WO2003013655A3 - Carbonic anhydrase inhibitors - Google Patents

Carbonic anhydrase inhibitors Download PDF

Info

Publication number
WO2003013655A3
WO2003013655A3 PCT/US2002/025447 US0225447W WO03013655A3 WO 2003013655 A3 WO2003013655 A3 WO 2003013655A3 US 0225447 W US0225447 W US 0225447W WO 03013655 A3 WO03013655 A3 WO 03013655A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbonic anhydrase
drugs
inhibitors
anhydrase inhibitors
cyclooxygenase
Prior art date
Application number
PCT/US2002/025447
Other languages
French (fr)
Other versions
WO2003013655A2 (en
Inventor
Janet M O'neal
Jaime L Masferrer
Original Assignee
Pharmacia Corp
Janet M O'neal
Jaime L Masferrer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Janet M O'neal, Jaime L Masferrer filed Critical Pharmacia Corp
Priority to EP02768491A priority Critical patent/EP1414522A2/en
Priority to AU2002331050A priority patent/AU2002331050A1/en
Priority to CA002456939A priority patent/CA2456939A1/en
Priority to JP2003518654A priority patent/JP2005501083A/en
Priority to BR0211836-0A priority patent/BR0211836A/en
Priority to MXPA04001268A priority patent/MXPA04001268A/en
Publication of WO2003013655A2 publication Critical patent/WO2003013655A2/en
Publication of WO2003013655A3 publication Critical patent/WO2003013655A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Methods of treating or preventing carbonic anhydrase associated disorders or diseases in a subject in need of such treatment as prevention comprising the administration of cyclooxygenase -2 inhibitors, or structurally related compounds, having carbonic anhydrase inhibitory properties, as well as combinations of the cyclooxygenase -2 inhibitors, or structurally related compounds, with anti- inflammatory agents or drugs, antineoplastic agents or drugs or ophthalmic agents or drugs in methods of treatment and prevention of disorders or diseases.
PCT/US2002/025447 2001-08-10 2002-08-09 Carbonic anhydrase inhibitors WO2003013655A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP02768491A EP1414522A2 (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitors
AU2002331050A AU2002331050A1 (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitors
CA002456939A CA2456939A1 (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitors
JP2003518654A JP2005501083A (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitor
BR0211836-0A BR0211836A (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitor
MXPA04001268A MXPA04001268A (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitor.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31156101P 2001-08-10 2001-08-10
US60/311,561 2001-08-10

Publications (2)

Publication Number Publication Date
WO2003013655A2 WO2003013655A2 (en) 2003-02-20
WO2003013655A3 true WO2003013655A3 (en) 2003-08-14

Family

ID=23207450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025447 WO2003013655A2 (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitors

Country Status (7)

Country Link
EP (1) EP1414522A2 (en)
JP (1) JP2005501083A (en)
AU (1) AU2002331050A1 (en)
BR (1) BR0211836A (en)
CA (1) CA2456939A1 (en)
MX (1) MXPA04001268A (en)
WO (1) WO2003013655A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
OA13170A (en) * 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
LT5504B (en) * 2006-08-02 2008-06-25 Biotechnologijos Institutas Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof
CA2777071A1 (en) * 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
BR112018000065B1 (en) * 2015-07-01 2023-11-07 Signalchem Lifesciences Corporation ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND THERAPEUTIC USES THEREOF IN THE TREATMENT OF CANCER

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
EP0826676A1 (en) * 1994-12-20 1998-03-04 Japan Tobacco Inc. Oxazole derivatives and use thereof
US5760068A (en) * 1993-11-30 1998-06-02 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5944021A (en) * 1995-06-07 1999-08-31 Rodriguez; Victorio C. Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema
WO2001028548A1 (en) * 1999-10-19 2001-04-26 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760068A (en) * 1993-11-30 1998-06-02 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
EP0826676A1 (en) * 1994-12-20 1998-03-04 Japan Tobacco Inc. Oxazole derivatives and use thereof
US5944021A (en) * 1995-06-07 1999-08-31 Rodriguez; Victorio C. Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO2001028548A1 (en) * 1999-10-19 2001-04-26 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRÜNEBERG, S. ET AL.,: "Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II.", ANGEW. CHEM. INT. ED., vol. 40, no. 2, - 2001, pages 389 - 393, XP001126207 *

Also Published As

Publication number Publication date
JP2005501083A (en) 2005-01-13
BR0211836A (en) 2004-12-14
EP1414522A2 (en) 2004-05-06
CA2456939A1 (en) 2003-02-20
MXPA04001268A (en) 2004-05-27
WO2003013655A2 (en) 2003-02-20
AU2002331050A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005009342A3 (en) Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2004072031A3 (en) Phenylacetamides and their use as glucokinase modulators
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2006033006A3 (en) Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2005007142A3 (en) Liquid compositions comprising formoterol
WO2002099388A3 (en) Benzodiazepine bradykinin antagonists
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2004041245A3 (en) Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
EP1440691A3 (en) Treatment of neurotic disorders
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
WO2003013655A3 (en) Carbonic anhydrase inhibitors
WO2004034987A3 (en) Treatment for reactive arthritis or bursitis
WO2003018535A3 (en) Novel aminobenzoephenones
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
WO2004047829A8 (en) New synergistic combination comprising roflumilast and formoterol
WO2004087157A3 (en) Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2456939

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001268

Country of ref document: MX

Ref document number: 2002768491

Country of ref document: EP

Ref document number: 2003518654

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002768491

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002768491

Country of ref document: EP